The effects of a mutant p53 protein on the proliferation and differentiation of PC12 rat phaeochromocytoma cells

Journal of Cellular Biochemistry

Volumn 99, Issue 5, 2006, Pages 1431-1441

  Fábián, Zsolt ^a   Vecsernyés, Mónika ^a   Pap, Marianna ^a   Szeberényi, József ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

ERK pathway; NGF; Stress signaling; V143A p53 mutation

Indexed keywords

DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN; NERVE GROWTH FACTOR; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; EARLY RESPONSE GENE; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; NERVE CELL DIFFERENTIATION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; ENHANCER ELEMENTS (GENETICS); ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE GROWTH FACTOR; NEURONS; PC12 CELLS; PHOSPHORYLATION; RATS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33751187663     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21019     Document Type: Article

References (34)

1. Boglari G, Erhardt P, Cooper GM, Szeberenyi J. 1998. Intact Ras function is required for sustained activation and nuclear translocation of extracellular signal-regulated kinases ih nerve growth factor-stimulated PC12 cells. Eur J Cell Biol 75:54-58.
2. Brooks CL, Gu W. 2003. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171.
3. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. 2003a. Signal transductibn mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 17:1263-1293.
4. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA. 2003b. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 22:469-480.
5. Chouinard N, Valerie K, Rouabhia M, Huot J. 2002. UVB-mediated activation of p38 mitogen-activated protein kinase enhances resistance of normal human keratinocytes to apoptosis by stabilizing cytoplasmic p53. Biochem J 365:133-145.
6. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S. 2002. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4:11-19.
7. Deffie A, Wu H, Reinke V, Lozano G. 1993. The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13:3415-3423.
8. Demidenko ZN, Fojo T, Blagosklonny MV. 2005. Complementation of two mutant p53: Implications for loss of heterozygosity in cancer. FEBS Lett 579:2231-2235.
9. Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. 1996. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 16:5178-5185.
10. Friedlander P, Haupt Y, Prives C, Oren M. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16:4961-4971.
11. Greene LA, Kaplan DR. 1995. Early events in neurotrophin signalling via Trk and p75 receptors. Curr Opin Neurobiol 5:579-587.
12. Greene LA, Tischler AS. 1976. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424-2428.
13. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
15. Hughes AL, Gollapudi L, Sladek TL, Neet KE. 2000. Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53. Simultaneous differentiation and proliferation subsequent to p53 functional inactivation. J Biol Chem 275:37829-37837.
16. Krause K, Haugwitz U, Wasner M, Wiedmann M, Mossner J, Engeland K. 2001. Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73. Biochem Biophys Res Commun 284:743-750.
17. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
18. Li M, Zhou JY, Ge Y, Matherly LH, Wu GS. 2003. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 278:41059-41068.
19. Lin AW, Lowe SW. 2001. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci USA 98:5025-5030.
20. Marshall CJ. 1995. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
21. Mayo LD, Donner DB. 2002. The PTEN, Mdm2, p53 tumor suppressor- oncoprotein network. Trends Biochem Sci 27:462-467.
22. Milczarek GJ, Martinez J, Bowden GT. 1997. p53 Phosphorylation: Biochemical and functional consequences. Life Sci 60:1-11.
23. Qui MS, Green SH. 1992. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron 9:705-717.
24. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW. 2002. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 277:12491-12494.
25. St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, Dastidar J, DaCosta A, Mattia M, Manfredi JJ. 2004. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: One involves direct binding to the cdc25C promoter. Mol Cell 16:725-736.
26. Szeberenyi J, Erhardt P. 1994. Cellular components of nerve growth factor signaling. Biochim Biophys Acta 1222:187-202.
27. Vaghefi H, Neet KE. 2004. Deacetylation of p53 after nerve growth factor treatment in PC12 cells as a posttranslational modification mechanism of neurotrophin-induced tumor suppressor activation. Oncogene 23:8078-8087.
28. Varley JM. 2003. Germline TP53 mutations and LiFraumeni syndrome. Hum Mutat 21:313-320.
29. Venanzoni MC, Robinson LR, Hodge DR, Kola I, Seth A. 1996. ETS1 and ETS2 in p53 regulation: Spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction. Oncogene 12:1199-1204.
30. Wu GS. 2004. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3:156-161.
31. Xu W, Cooper GM. 1995. Identification of a candidate c-mos represser that restricts transcription of germ cell-specific genes. Mol Cell Biol 15:5369-5375.
32. Xu D, Wilson TJ, Chan D, De Luca E, Zhou J, Hertzog PJ, Kola I. 2002. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. Embo J 21:4081-4093.
33. Yaka R, Gamliel A, Gurwitz D, Stein R. 1998. NGF induces transient but not sustained activation of ERK in PC12 mutant cells incapable of differentiating. J Cell Biochem 70:425-432.
34. Yap DB, Hsieh JK, Zhong S, Heath V, Gusterson B, Crook T, Lu X. 2004. Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res 64:4749-4754.